I don't understand your post.
They already received fast track
Vericel Receives FDA Fast Track Designation for Ixmyelocel-T
7:41 am ET February 21, 2017 (Benzinga) Print
Vericel Corporation (NASDAQ: VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has designated the investigation of ixmyelocel-T for reduction in the risk of death and cardiovascular hospitalization in patients with chronic advanced heart failure due to ischemic dilated cardiomyopathy as a Fast Track Development Program.